On May 7, 2024, X4 Pharmaceuticals, Inc. (XFOR) announced financial results for the first quarter of 2024. The company will be hosting an investor event in June 2024 to present interim results from the ongoing Phase 2 trial of mavorixafor in chronic neutropenia (CN). The company has initiated the launch of XOLREMDI (mavorixafor) for use in patients 12 years of age and older with WHIM syndrome. We continue to expect that X4 will monetize the Rare Pediatric Disease Priority Review Voucher (PRV) in the near future. X4 will be initiating a Phase 3 trial of mavorixafor in CN in the second quarter of 2024 to evaluate its effect with or without G-CSF in people with congenital or acquired primary autoimmune and idiopathic CN who are experiencing recurrent and/or serious infections.
08 May 2024
XFOR: Data from Phase 2 CN Trial Expected in June 2024
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
XFOR: Data from Phase 2 CN Trial Expected in June 2024
- Published:
08 May 2024 -
Author:
David Bautz -
Pages:
7
On May 7, 2024, X4 Pharmaceuticals, Inc. (XFOR) announced financial results for the first quarter of 2024. The company will be hosting an investor event in June 2024 to present interim results from the ongoing Phase 2 trial of mavorixafor in chronic neutropenia (CN). The company has initiated the launch of XOLREMDI (mavorixafor) for use in patients 12 years of age and older with WHIM syndrome. We continue to expect that X4 will monetize the Rare Pediatric Disease Priority Review Voucher (PRV) in the near future. X4 will be initiating a Phase 3 trial of mavorixafor in CN in the second quarter of 2024 to evaluate its effect with or without G-CSF in people with congenital or acquired primary autoimmune and idiopathic CN who are experiencing recurrent and/or serious infections.